

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the below date:
Date: July 21, 2005 Name: John Murray, Ph.D. Signature: John Murray

**BRINKS
HOFER
GILSON
& LIONE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Charkrabarty et al.

Appln. No.: 10/720,603

Examiner: N/A

Filed: November 24, 2003

Art Unit: N/A

For: Cytotoxic Factors For Modulating Cell Death

Attorney Docket No: 11472/11

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir:

Attached is/are:

Second Supplemental Information Disclosure Statement, Form PTO 1449 with references
 Return Receipt Postcard

Fee calculation:

No additional fee is required.
 Small Entity.
 An extension fee in an amount of \$____ for a ____-month extension of time under 37 C.F.R. § 1.136(a).
 A petition or processing fee in an amount of \$____ under 37 C.F.R. § 1.17(____).
 An additional filing fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Small Entity		Not a Small Entity		
					Rate	Add'l Fee	or	Rate	Add'l Fee
Total		Minus			x \$25=			x \$50=	
Indep.		Minus			x 100=			x \$200=	
First Presentation of Multiple Dep. Claim					+\$180=			+\$360=	
					Total	\$		Total	\$

Fee payment:


A check in the amount of \$____ is enclosed.
 Please charge Deposit Account No. 23-1925 in the amount of \$____. A copy of this Transmittal is enclosed for this purpose.
 Payment by credit card in the amount of \$____ (Form PTO-2038 is attached).
 The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,

John Murray, Ph.D. (Reg. No. 44,251)

July 21, 2005

Date



I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

COMMISSIONER FOR PATENTS
P.O. BOX 1450 ALEXANDRIA, VA 22313-1450
on July 21, 2005

Date of Deposit

John Murray

Name of applicant, assignee or
Registered Representative

John Murray

Signature

July 21, 2005

Date of Signature

Our Case No. 11472/11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Charkrabarty *et al.*

Serial No.: 10/720,603

Filing Date: November 24, 2003

For: Cytotoxic Factors For Modulating
Cell Death

Examiner: Not assigned

Group Art Unit No.: Not Assigned

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

COMMISSIONER FOR PATENTS
P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on the attached Form PTO-1449 be considered by the Examiner and made of record.

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is believed to be filed before the mailing of the first Office Action on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

This application claims benefit of provisional application number 60/414,550, filed August 15, 2003, and is a continuation-in-part of U.S. Patent Application Serial Number 10/047,710, filed January 15, 2002, which claims benefit of provisional application U.S. Ser. No. 60/269,133, filed February 15, 2001. These prior applications are relied upon for an earlier filing dated under 35 U.S.C. §§ 119 and 120. The following documents are cited:

US 5,681,810	Oct 28, 1997	Villemez et al.
US5,972,899	Oct 26, 1999	Zychlinsky et al.

Vasu Punj et al., "Bacterial Cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer", Oncogene (2004) 23, 2367-78.

Voet et al., (Biochemistry, 1990, John Wiley & Sons, pp. 415-17, 932 and 933)


Definition of "necrosis" as "to make dead" according to Merriam-Webster Online dictionary downloaded from URL>>www.m-w.com on 4/25/2005

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed non U.S. patent reference for which a copy is required under 37 C.F.R. §1.98(a)(2).

If, for any reason, the Examiner feels that an interview would be helpful to resolve any issues, he is respectfully requested to contact the undersigned attorney at (312) 321-4229.

Respectfully submitted,

Date: July 21, 2005


John Murray, Ph.D.
Registration No. 44,251
Attorney for Applicant

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200



FORM PTO-1449	SERIAL NO. 10/720,603	CASE NO. 11472/11
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE November 24, 2003	GROUP ART UNIT Not Assigned
(use several sheets if necessary)	APPLICANT(S): Das Gupta et al.	

REFERENCE DESIGNATION
U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
C1	US 5,681,810	Oct 28, 1997	Villemez et al.		
C2	US5,972,899	Oct 26, 1999	Zychlinsky et al.		

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)	
	C3	Vasu Punj et al., "Bacterial Cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer", Oncogene (2004) 23, 2367-78.
	C4	Voet et al., (Biochemistry, 1990, John Wiley & Sons, pp. 415-17, 932 and 933)
	C5	Definition of "necrosis" as "to make dead" according to Merriam-Webster Online dictionary downloaded from URL>>www.m-w.com on 4/25/2005

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.